Public DatasetFree · Citable · Updated

Compounding Pharmacy Compliance Map

Public-records dataset of 15 major US compounding pharmacies serving telehealth and DTC health operators in 2026. 503A vs 503B classification, specialty focus, recent FDA enforcement history, and state-specific rules — consolidated so operators can evaluate compounding partners without monitoring 50 state pharmacy boards and the FDA enforcement database individually.

Operators: cross-reference your current compounding partner against this dataset. Attorneys, journalists, researchers: cite freely.

2026 GLP-1 compounding regulatory state — what changed

  • • May 2026: FDA formally proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. 503B outsourcing facilities can no longer compound these GLP-1s from bulk.
  • • April 2026: FDA clarified that 503A patient-specific compounding can continue with documented medical need (limit ~4 prescriptions/month of same formulation per pharmacy).
  • • Feb 2025: FDA declared semaglutide shortage resolved.
  • • Dec 2024: FDA declared tirzepatide shortage resolved.
  • • Practical impact: Most large-scale 503B GLP-1 production has wound down. Continued GLP-1 compounding is now primarily 503A patient-specific — much smaller scale, with documented medical need required.
15 of 15 pharmacies match

Strive Pharmacy

Strive Specialties, Inc.
Elevated risk
503A HQ: ArizonaEst. 2018
Specialties
GLP-1Weight LossWellnessHormone
States served (claim)
All 50 (company claim — verify per state)

9 locations; PCAB/NABP/LegitScript accredited. Supplied Hims & Hers GLP-1 until Feb 2025 split after oral semaglutide controversy. Sued by Eli Lilly April 2025; filed antitrust countersuit against Lilly + Novo Jan 2026. AZ Board of Pharmacy inspection Sept 2025 cited continued single-ingredient GLP-1 compounding after shortage exemption ended.

Company site

Empower Pharmacy

Empower Clinic Services, LLC
High risk
Both HQ: Texas
Specialties
GLP-1HormoneMen's HealthGeneral Compounding
States served (claim)
Many states (multi-state nonresident permits verified)

Described as North America's largest compounding facility. FDA Form 483 May 2024 (fill weight discrepancies in semaglutide). FDA Warning Letter April 2025 (insanitary conditions in sterile prep). Sued by Eli Lilly July 2025. Co-filed tirzepatide patent challenge with BPI Labs.

Company site

BPI Labs

Belcher Pharmaceuticals, LLC
Watch list
503B HQ: Florida
Specialties
GLP-1Sterile Injectables
States served (claim)
Unverified

Only FDA-registered drug manufacturer also operating a 503B GLP-1 line. Robotic aseptic filling, in-house batch testing. FDA Form 483 Feb 2025 cited missing 'Office Use Only' labeling on semaglutide/tirzepatide vials. Joined Empower in tirzepatide patent challenge.

Company site

Hallandale Pharmacy

Watch list
503A HQ: FloridaEst. 2004
Specialties
GLP-1General Compounding
States served (claim)
Many states (multi-state nonresident permits verified)

60,000 sq ft facility, PCAB-accredited. FDA Warning Letter March 2020 (no valid patient-specific prescriptions, insanitary conditions); closeout May 2022. Confirmed partner of Zappy Health and other telehealth platforms.

Company site

Olympia Pharmaceuticals

Watch list
Both HQ: FloridaEst. 1989
Specialties
GLP-1PeptidesWeight MgmtHormone
States served (claim)
Many states (multi-state nonresident permits verified)

Only 503B outsourcing facility in Central FL. Opened sister facility Wesley Pharmaceuticals May 2025, scaling from 150K to 450K vials/week. FDA Form 483 May 2024 (semi-annual reporting failure, not sterility). Currently compounds liraglutide; dropped sema/tirz after shortage end.

Company site

Wells Pharmacy Network

No recent action
Both HQ: Florida
Specialties
Hormone PelletsWellnessAnti-AgingWeight MgmtSexual Wellness
States served (claim)
Many states (multi-state nonresident permits verified)

20,500 sq ft 503A + 20,000 sq ft FDA-registered 503B outsourcing facility. Best known for sterile hormone pellet implants. Not a primary GLP-1 telehealth supplier; serves 49 states + Puerto Rico per company.

Company site

Belmar Pharma Solutions

No recent action
Both HQ: ColoradoEst. 1985
Specialties
Women's HormoneMen's HealthLongevityWellness
States served (claim)
All 50 (company claim — verify per state)

Operates 6 x 503A pharmacies and 2 x 503B outsourcing facilities. Hormone-focused rather than GLP-1 primary. Ships nationwide since 1985.

Company site

AnazaoHealth

Fagron
No recent action
Both HQ: FloridaEst. 1997
Specialties
HormoneWeight MgmtIV TherapySexual WellnessAestheticsNuclear Medicine
States served (claim)
Many states (multi-state nonresident permits verified)

54,000 sq ft 503A in Tampa + 30,000 sq ft 503B in Las Vegas. Owned by Fagron (global compounding leader). Multi-specialty supplier to telehealth and aesthetic platforms.

Company site

ReviveRX

High risk
503A HQ: Texas
Specialties
HormoneWeight MgmtPeptidesWellnessSexual Wellness
States served (claim)
Unverified

FDA Class I recall April 2024: mislabeled tirzepatide vials actually contained testosterone cypionate. Significant patient-safety enforcement event triggering ongoing litigation exposure.

Company site

Tailor Made Compounding

Noom (acquired 2022)
Elevated risk
503A HQ: Kentucky
Specialties
HormonePeptidesAnti-Aging
States served (claim)
Unverified

Pleaded guilty federally to distributing unapproved new drugs (SARMs, BPC-157, CJC-1295, ipamorelin, melanotan II, etc.); forfeited $1.78M. Acquired by Noom to fuel weight-loss expansion. Notable federal criminal-enforcement history.

Company site

University Compounding Pharmacy

Fagron (acquired Jan 2026)
No recent action
503A HQ: CaliforniaEst. 1993
Specialties
HormoneUrologyOphthalmologyDermatology
States served (claim)
Unverified

Acquired by Fagron January 2026. Not primarily a GLP-1 telehealth supplier; broad specialty 503A compounder.

Company site

Carie Boyd Pharmaceuticals

Right Value Drug Stores, LLC
High risk
503B
Specialties
Sterile CompoundingGeneral Compounding
States served (claim)
Unverified

FDA Warning Letter Sept 2021; second FDA Warning Letter Dec 2024 citing serious sterile-prep deficiencies. Repeat enforcement target.

Company site

Red Rock Pharmacy

No recent action
503A HQ: UtahEst. 2017
Specialties
GLP-1Closed-Door
States served (claim)
Many states (multi-state nonresident permits verified)

USP 795/797/800 compliant. Tirzepatide formulated with glycine. Nationwide telehealth shipping.

Company site

Contigo Compounding (Eden Pharmacy)

Eden Health (acquired Aug 2025)
Watch list
503A
Specialties
GLP-1Personalized
States served (claim)
Unverified

Acquired by Eden Health Aug 2025; now Eden's in-house captive 503A. Sterile hazardous lab opens to third-party telehealth partners in underserved states.

Company site

Precision Compounding (Precision Telemed)

Watch list
503A
Specialties
GLP-1
States served (claim)
Unverified

Telehealth-integrated. Former Eden Health partner pharmacy. Each prescription accompanied by Certificate of Analysis.

Company site

Documented 2024-2026 Enforcement Actions

Public-records timeline of FDA, state pharmacy board, and litigation events affecting compounding pharmacies serving telehealth operators. Sourced from FDA Form 483 / Warning Letter database, state board orders, and court filings.

2026-05
FDAProposed Rule→ All 503B outsourcing facilities

FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list permanently — 503B facilities can no longer compound these from bulk.

2026-04
FDAClarification→ 503A pharmacies — GLP-1 supply policy

FDA clarified that 503A patient-specific compounding of GLP-1 medications can continue with documented medical need (limit ~4 prescriptions/month of same formulation per pharmacy).

2026-01-16
FDACDER Warning Letter→ Kennett Square, PA compounder

Sterility and potency failures in sema/tirz compounding.

2025-09
FDAWarning Letters (50+)→ GLP-1 compounders and manufacturers

Mass enforcement wave citing false 'generic'/'same active ingredient' claims in compounded GLP-1 marketing.

2025-09-04
StateAZ Board of Pharmacy inspection finding→ Strive Pharmacy

Continued single-ingredient sema/tirz compounding cited after FDA shortage exemption ended.

2025-08-04
PrivateCivil lawsuits→ 12 defendants including pharmacies, medspas, telehealth platforms

Novo Nordisk filed multi-defendant suit over compounded semaglutide marketing and sourcing.

2025-07-25
PrivateCivil lawsuit→ Empower Clinic Services

Eli Lilly sued Empower in S.D. Texas over compounded tirzepatide.

2025-04
FDAWarning Letter→ Empower Pharmacy

Insanitary conditions in sterile drug prep, microbial contamination response failures.

2025-02
FDAForm 483→ BPI Labs

Missing 'Office Use Only' labeling on sema/tirz vials.

2025-02
FDAShortage Resolved→ All compounders — semaglutide

FDA declared semaglutide shortage resolved; 60-90 day compounding wind-down clock started.

2024-12-17
FDAWarning Letter (second)→ Carie Boyd Pharmaceuticals

Repeat sterile-prep deficiencies, second Warning Letter.

2024-12-04
FDAShortage Resolved→ All compounders — tirzepatide

FDA declared tirzepatide shortage resolved; compounding wind-down clock started.

2024-05-31
FDAForm 483→ Carie Boyd Pharmaceuticals

503B violations cited during inspection.

2024-05
FDAForm 483→ Olympia Pharmaceuticals

Failure to file required 503B semi-annual product identification reports.

2024-05
FDAForm 483→ Empower Pharmacy

Fill weight discrepancies in semaglutide vials, inadequate QC sampling, aseptic processing deficiencies.

2024-04-20
FDAClass I Recall→ ReviveRX

Mislabeled tirzepatide vials actually contained testosterone cypionate.

State Enforcement Posture

States with distinctive compounding regulations or enforcement priorities that affect out-of-state pharmacies shipping to their residents.

Mississippi

Medical board rule restricts weight-loss prescribing to FDA-approved-for-weight-loss drugs only — effectively bans compounded GLP-1 for weight loss.

Source: Mississippi State Board of Medical Licensure

California

AB 1990 — pharmaceutical-grade ingredient certifications required; fines up to $1,000/dose plus license revocation for non-compliance.

Source: California Business & Professions Code (AB 1990)

Massachusetts

Among the strictest nonresident sterile/complex non-sterile compounding licensure regimes; requires disclosure of out-of-state enforcement actions on application and renewal.

Source: Massachusetts Board of Pharmacy

Nevada

$250 annual per-pharmacist registration fee for nonresident compounders/dispensers (2024 rule).

Source: Nevada Board of Pharmacy

Texas

Class E-S nonresident sterile compounding permits require recent third-party inspection report from approved vendor.

Source: Texas State Board of Pharmacy

Citing this dataset

This dataset is free for healthcare attorneys, journalists, compliance officers, researchers, and operators to cite, reference, or link. We aggregate from public records (FDA, state pharmacy boards, court filings, press releases) and consolidate so the data is usable.

Suggested citation
TrueEval Compounding Pharmacy Compliance Map. https://trueeval.com/compounding-pharmacy-map. Accessed November 20, 2026.

Submit corrections or new enforcement events: (844) 771-7836

Methodology: Evidence sourced from state medical board orders, pharmacy board actions, DEA bulletins, FDA guidance, and published statutes. AI-assisted summarization; scoring is deterministic. Scope: Informational only — not legal, accounting, or medical advice. No attorney-client, accountant-client, or provider-patient relationship is established.